R-Tech Ueno: Announcement of Additional Extension of the Date of the Deadline for Rendering the Arbitration Decision against Takeda Pharmaceuticals Company Limited
07/01/2012| 09:25pm US/Eastern
Ueno (JASDAQ: 4573) has announced that it has been notified by the
International Court of Arbitration, International Chamber of Commerce
(ICC), that the date of the deadline for rendering the arbitration
decision has again been extended and is now July 31, 2012. R-Tech Ueno
had previously announced in its press
release on May 31, 2012 that it had been notified by the ICC that
the date of the deadline for rendering the arbitration decision had been
extended to June 29, 2012.
R-Tech Ueno is a bio venture company established
in September 1989 for the purpose of R&D and marketing of drugs. Under
the leadership of the CEO, also a medical doctor, the company is
developing new drugs on the theme "Physician-Oriented New Drug
Innovation", targeting ophthalmologic and dermatologic diseases that
previously had no effective therapeutic agent.
We aim at becoming a "global pharmaceutical company specializing in
specific fields (ophthalmology and dermatology) and developing and
selling pharmaceutical products through the eyes of doctors." We are
promoting the development of new drugs for unmet medical needs for which
the government provides recommendations and assistance, orphan drugs and
the drugs in the field of anti-aging (lifestyle drugs).
About Sucampo Pharmaceuticals, Inc.
Inc., an international pharmaceutical company, is focused on the
discovery, development and commercialization of proprietary drugs based
on prostones. The therapeutic potential of prostones, which occur
naturally in the human body as a result of enzymatic, 15-PGDH,
transformation of certain fatty acids, was first identified by Ryuji
Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief
Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with
Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently
Advisor, International Business Development and a member of the Board of
For more information about Sucampo Pharmaceuticals, please visit http://www.sucampo.com./
R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
© Business Wire 2012